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Abstract
Background In vivo reflectance confocal microscopy (RCM) is a promising non-invasive skin imaging technique that
could facilitate early diagnosis of basal cell carcinoma (BCC) instead of routine punch biopsies. However, the clinical
value and utility of RCM vs. a punch biopsy in diagnosing and subtyping BCC is unknown.
Objective To assess diagnostic accuracy of RCM vs. punch biopsy for diagnosing and subtyping clinically suspected
primary BCC.
Methods A prospective, consecutive cohort of 100 patients with clinically suspected BCC were included at two tertiary
hospitals in Amsterdam, the Netherlands, between 3 February 2015 and 2 October 2015. Patients were randomized
between two test-treatment pathways: diagnosing and subtyping using RCM imaging followed by direct surgical exci-
sion (RCM one-stop-shop) or planned excision based upon the histological diagnosis and subtype of punch biopsy
(standard care). The primary outcome was the agreement between the index tests (RCM vs. punch biopsy) and reference
standard (excision specimen) in correctly diagnosing BCC. The secondary outcome was the agreement between the
index tests and reference standard in correctly identifying the most aggressive BCC subtypes.
Results Sensitivity to detect BCC was similar for RCM and punch biopsy (100% vs. 93.94%), but a punch biopsy was
more specific than RCM (79% vs. 38%). RCM expert evaluation for diagnosing BCC had a sensitivity of 100% and a
specificity of 75%. The agreement between RCM and excision specimen in identifying the most aggressive BCC subtype
ranged from 50% to 85% vs. 77% by a punch biopsy.
Conclusion Reflectance confocal microscopy and punch biopsy have comparable diagnostic accuracy to diagnose
and subtype BCC depending on RCM experience. Although experienced RCM users could accurately diagnose BCC at
a distance, we found an important difference in subtyping BCC. Future RCM studies need to focus on diagnostic accu-
racy, reliability and specific criteria to improve BCC subtype differentiation.
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Introduction
Current international guidelines recommend a punch biopsy of
clinically suspected basal cell carcinoma (BCC) to confirm clinical
diagnosis and classify into histological subtypes (superficial,
nodular and aggressive) to ensure optimal treatment selection.1,2
Although considered as the most reliable diagnostic technique, a
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punch biopsy fails to diagnose an aggressive subtype in up to one
of six BCCs.3 Other obvious disadvantages of a punch biopsy are
pain and discomfort for the patient, scarring, doctor’s delay in the
diagnostic process and costs for the healthcare system.
Ideally, BCC diagnosing and subtyping should be performed
non-invasively by a painless procedure leading to an immediate
diagnosis and treatment. This could be particularly relevant to
the growing use of topical treatments as non-surgical first-line
therapy for superficial BCC.4 As for nodular and aggressive
BCC, surgical treatment with excision margins of, respectively, 3
or 5 mm remains the treatment of choice, reserving Mohs
micrographic surgery for primary BCC on high-risk facial areas
(depending on tumour size) and recurrent or previously incom-
pletely excised BCC in all facial areas.5–8
Recently, we performed a randomized controlled trial to
assess the efficacy of a one-stop-shop concept with real-time
in vivo reflectance confocal microscopy imaging (RCM) vs. stan-
dard care for surgical treatment of BCC.9 To determine the clini-
cal value and utility of RCM vs. a punch biopsy in diagnosing
and subtyping BCC, a diagnostic analysis is needed. Besides, pre-
vious diagnostic testing of RCM and punch biopsy for BCC was
not done in accordance with the Standards of Reporting of Diag-
nostic Accuracy (STARD).3,10,11
The aim of this study was to assess diagnostic accuracy of




Diagnostic accuracy data were prospectively collected alongside
the multicentre non-inferiority clinical trial in which patients
with clinically suspected primary BCC were randomized between
two test-treatment pathways: diagnosing and subtyping using
RCM followed by direct surgical excision (RCM one-stop-shop)
or planned excision based upon the histological diagnosis and
subtype of a punch biopsy (standard care). Full details of the
clinical trial are given elsewhere.12
Participants
Between 3 February 2015 and 2 October 2015, 100 patients pre-
senting with clinically suspected BCC were consecutively
included at the Department of Dermatology, Academic Medical
Centre, University of Amsterdam (coordinating tertiary hospi-
tal), and the Department of Dermatology, the Netherlands Can-
cer Institute (participating tertiary hospital), in Amsterdam, the
Netherlands. We included patients older than 18 years with pre-
viously untreated lesions, lesions suitable for conventional surgi-
cal excision and lesions present for at least 1 month. We
excluded lesions on high-risk areas of the face (H-zone and
ears), lesions larger than 20 mm, recurrent BCC, lesions not
suitable for RCM (macroscopic ulceration or crust) and patients
with basal cell nevus syndrome. Immunocompromised patients
were not excluded.
Initial clinical assessment, most times including dermoscopy,
was performed by experienced dermatologists. Patients with
multiple clinically suspected new primary BCC were included
for only one lesion being the most suitable for conventional sur-
gical treatment according to the following order: (i) chest, (ii)
extremities, and (iii) head and neck area.
Test methods
RCM (index test 1) Patients allocated to the RCM one-stop-
shop group prospectively received RCM (VivaScope 1500;
CaliberID, Henrietta, NY, USA; MAVIG GmbH, M€unchen,
Germany) to diagnose and subtype BCC followed by direct
surgical excision according to previously published proto-
col.12 DK performed RCM imaging including subsequent
diagnosing of RCM cases at the Academic Medical Centre,
and YE did the same at the Netherlands Cancer Institute.
At the time of RCM, both assessors were masked to the
results of surgical excision specimen but not to patients’
clinical history.
Prior to the study, DK and YE were trained in RCM and
interpretation of the acquired images during a 1 week ‘Expert
training in Confocal Laser Scanning Microscopy’ course orga-
nized by MAVIG GmbH (distributor of the VivaScope device)
at the University of Modena in Italy. DK and YE had <1 year of
RCM experience prior to the start of the study. After the trial
was completed two independent international RCM experts (CL
and MU) evaluated the RCM images for BCC presence and sub-
type through a secured online teleconsultation platform
designed to share RCM cases (VivaNet, MAVIG, GmbH).13
The experts were masked to the results of surgical excision speci-
men as well as patients’ clinical history. Both experts had more
than 10 years RCM experience.
Punch biopsy (index test 2) Patients allocated to the standard
care group received planned excision after a punch biopsy
was performed. The routine 3-mm punch biopsy was per-
formed from the most elevated part of the lesion using infil-
tration anaesthesia (2% xylocaine/adrenaline 1 : 80 000).
Biopsy specimens were subsequently analysed by an experi-
enced pathologist within 2 weeks. Surgical excision of the
lesion with adequate margins was performed within the fol-
lowing 4 weeks after receiving the report of the punch
biopsy. At the time of the punch biopsy, the pathologists
were masked to the results of surgical excision specimen but
not to patients’ clinical history.
Surgical excision (reference standard) Histopathological con-
firmation of presence and subtype of BCC and inspection of
resection margins with the use of haematoxylin and eosin
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stained sections taken from the excision specimen was defined as
the reference standard.
An independent dermatologist or independent dermatology
resident supervised by a dermatologist performed surgery under
local anaesthetics (2% xylocaine/adrenaline 1 : 80 000) followed
by primary wound closure in both treatment groups. Clinically
suspected BCCs that were not confirmed by either RCM or
punch biopsy were surgically treated with a 3-mm excision
margin. To prevent bias DK and YE did not perform the
subsequent surgical procedures.
After formalin fixation and treatment of resection borders
with ink, standard vertical section processing of the surgical
excision specimen was used. Reporting of histopathological
findings was performed by an experienced pathologist within
2 weeks after surgery. During assessment of the reference
standard, the pathologist was masked to the results of clini-
cal assessment and RCM but not to the results of a punch
biopsy and patients’ clinical history. In line with standard
care, the pathologist re-evaluated the results of a punch
biopsy during the assessment of the excision specimen in
cases of doubt. Besides, a biopsy scar could be recognized
in excision specimen.
Analysis
We recorded the following characteristics of participants and
tumours at baseline and summarized them for each treatment
group with descriptive statistics: age, gender, skin type, previous
BCC, study site, immune status, tumour diameter and tumour
localization. Rippey’s classification was used for classifying BCC
subtypes.14 A distinction was made between superficial, nodular
and aggressive (micronodular, infiltrating and basosquamous)
growth patterns. In the case of mixed-type diagnosis, defined as
two or more single growth patterns, the most aggressive compo-
nent was used for analysis. Diagnoses of BCC and subtype by
RCM vs. punch biopsy were separately compared to surgical
excision for all tumours. The primary outcome was the agree-
ment between the index tests (RCM vs. punch biopsy) and refer-
ence standard (excision specimen) in correctly diagnosing BCC.
The secondary outcome was the agreement between the index
tests and reference standard in correctly identifying the most
aggressive BCC subtypes. We excluded from the analyses cases in
which RCM or a punch biopsy was indeterminate and cases in
which subsequent surgical excision was not performed. Reasons
for not performing surgical excision were recorded.
The number of true and false positives as well as true and false
negatives was recorded. We established the sensitivity, speci-
ficity, positive and negative likelihood ratios, and predictive val-
ues for diagnosing BCC. For BCC subtyping, concordant results
were calculated as the proportion of tumours with the corre-
sponding subtype diagnosis in RCM or punch biopsy compared
to excision specimen. The statistical analysis was performed
using SPSS version 21.0 (SPSS Inc., Chicago, IL, USA).
Results
Participants
A total of 50 patients were randomized to RCM one-stop-shop
(48 received index test and treatment) and 50 to standard care
(47 received index test and treatment) (Fig. 1). Five patients
were excluded, two patients in the RCM one-stop-shop group
who did not receive imaging and three patients in the standard
care group who did not receive surgical treatment (Fig. 1).
Baseline characteristics are shown in Table 1. In the RCM on-
stop-shop group, 40 BCCs were confirmed by surgical excision
specimen compared to 33 BCCs in the standard care group.
Most of the BCC had a superficial or nodular subtype. All
patients in the RCM one-stop-shop group received surgical
treatment directly after RCM at the same initial outpatient visit.
The average time between the initial visit and surgical treatment
in the standard care group was almost 10 weeks (66 days).
Test results
The RCM experts evaluated the images that were acquired at the
Department of Dermatology, Academic Medical Centre, Univer-
sity of Amsterdam (coordinating tertiary hospital). CL evaluated
32/36 cases, and MU evaluated 36/36 cases.
RCM vs. punch biopsy for diagnosing BCC Table 2 shows the
agreement between specimens in correctly diagnosing BCC. Sen-
sitivity to detect BCC was similar for RCM and punch biopsy
(100% [90.75–100] vs. 93.94% [79.77–99.26]), but a punch
biopsy was more specific than RCM (79% [49.20–95.34] vs. 38%
[8.52–75.51]).
The RCM expert evaluation for diagnosing BCC was the same
for both readers with a sensitivity of 100% [85.75–100] and a
specificity of 75% [34.91–96.81].
RCM vs. punch biopsy for subtyping BCC Table 3 shows the
agreement between RCM vs. a punch biopsy compared to exci-
sion in correctly identifying the most aggressive BCC subtypes.
The overall agreement was 68% for RCM (26/38 concordant
RCM cases) vs. 77% for punch biopsy (24/31 concordant punch
biopsy cases). The initial RCM assessment during the trial period
led to overstaging of BCC subtype in 18% (7/38) vs. 10% (3/31)
by punch biopsy. Understaging of BCC subtype was seen in 13%
of both RCM and a punch biopsy (5/38 vs. 4/31).
The agreement between BCC subtype of the RCM experts and
excision specimen ranged from 50% (12/24 concordant RCM
cases diagnosed by CL) to 85% (23/27 concordant RCM cases
diagnosed by MU) (Table 3). Overstaging of BCC subtype by
RCM expert teleconsultation assessment after the trial period
ranged from 11% (3/27) to 50% (12/24). Understaging of BCC
subtype by RCM experts ranged from 0% to 4% (1/27).
There were no adverse events after performing RCM or punch
biopsies. Adverse reactions after performing surgical excision
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• 1 due to technical 
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imaging device
Excluded, n = 113
• 68 lesions on high-risk localisation 
• 14 declined to participate
• 13 treated or recurrent lesions
• 10 lesions not suitable for confocal imaging 
• 3 lesions larger than 20mm
• 2 technical malfunction confocal imaging device 
• 2 planned holidays on short term
• 1 was not able to understand study procedure
Figure 1 Flow chart. BCC, basal cell carcinoma; PDT, photodynamic therapy. Two patients in the RCM one-stop-shop group did not
begin diagnosis and treatment. One refused directly after randomization, and the other one could not participate due to technical mal-
function of the confocal imaging device. *Three patient in the standard care group did not receive subsequent surgical excision after the
punch biopsy. In one patient, the protocol was violated after histological assessment of punch biopsy specimen showed actinic keratosis
with no visible signs of the biopsied lesion on the day of surgery. Another patient with a histologically confirmed superficial BCC was mis-
takenly treated with photodynamic therapy instead of surgery. The last patient with a histologically confirmed BCC developed a large
leiomyosarcoma on the same localization. Surgical excision of the BCC was cancelled, and the patient was referred to an oncologic sur-
geon to treat the leiomyosarcoma. **In the standard care group, a punch biopsy identified three lesions as BCC while surgical excision
specimen did not show (residual) histological signs of BCC. ***RCM incorrectly identified five lesions as BCC while surgical excision
specimen diagnosed two non-malignant lesions, one actinic keratosis, one Bowen’s disease and one squamous cell carcinoma. ****In
the RCM one-stop-shop group, two histology proven BCC (excision specimen) cases were tested as inconclusive, one ulcerating lesion
and one lesion with a superficial crust.
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included four patients of the RCM one-stop-shop group with
postoperative wound infections. In all cases, the infection was
successfully treated with oral antibiotics, without the need of
hospitalization. One patient of the standard care group using
anticoagulant medication developed an excessive postoperative
bleeding requiring hospitalization for 3 days. She fully recov-
ered. This was reported as the only serious adverse event.
Discussion
Our findings show that for experienced users, RCM can have a
similar diagnostic accuracy to diagnose and subtype clinically
suspected BCC compared to a punch biopsy.
This is the first study that prospectively compared RCM with
a punch biopsy for diagnosing and subtyping BCC. Previous
RCM studies for diagnosing BCC showed varying high sensitiv-
ity and specificity values ranging from 85% to 97% and from
89% to 99%, respectively.15 However as reported by Que et al.,
most of these studies involved RCM experts with prior experi-
ence in RCM interpretation.15 Our results confirm the high sen-
sitivity of RCM for diagnosing BCC (100%), but the specificity
ranged from 38% (RCM users with <1 year experience) to 75%
(RCM experts with more than 10 years of experience). We cau-
tion that the range of specificities for confirming BCC diagnosis
is large for both RCM (DK/YE 38% [8.52–75.51] vs. CL/MU
75% [34.91–96.81]) and a punch biopsy (79% [49.20–95.34]). A
lower RCM specificity was previously reported by Rao et al.16
that studied RCM users with varying levels of experience. Fur-
thermore, Farnetani et al.17 also recently emphasized on the
importance of the RCM learning curve and confirmed that diag-
nostic accuracy of RCM increases with experience.
The agreement between histological subtype on a punch
biopsy and surgical excision specimen in our study was 77%
(24/31 concordant cases). This seems consistent with previous
studies. Interestingly, we found that RCM proved to be almost
as reliable for accurately subtyping BCC (68%, 26/38 concordant
cases). However, we also found a large difference in subtyping
BCC between RCM experts. This is an important finding that
highlights the need for further training, guidelines and protocols
for subtyping BCC using RCM.
With the growing number of patients suffering from BCC,
new management strategies are needed.18 Non-invasive skin
imaging could play a crucial role in improving BCC health care
for both patients and clinicians.19 Previous diagnostic RCM
studies have primarily focused on test accuracy (sensitivity and
specificity for diagnosing BCC). However, other aspects such as
time between diagnosis and treatment, direct health effects of
testing, costs of testing and patients’ emotional and behavioural
responses to testing should also be taken into consideration.20,21
In our proposed RCM one-stop-shop, we have assessed the effi-
cacy of such a test-treatment pathway. The main advantages of
using RCM include an immediate diagnosis and treatment for
patients suffering from BCC opposed to painful skin biopsies
with a doctor delay in the diagnostic process. Moreover in
selected cases of superficial BCC, patients could benefit from a
totally non-invasive disease management.22
Study strengths include adherence to the STARD guidelines.10
Furthermore, we prevented sampling error using final surgical
excision specimen as our reference standard instead of a punch
biopsy. We also prevented heterogeneity of our results using pre-
defined RCM criteria and using the same VivaScope 1500
device at both participating centres. Although it may not be in
line with daily practice to surgically treat superficial BCC, it was
important in our study to histologically confirm all types of
BCC and to prevent selection bias for specific BCC subtypes.
Table 1 Tumour and patient characteristics separated by treat-
ment group
One-stop-
shop (n = 50)
Standard of
care (n = 50)
Age (years) 64 (39–88) 68 (41–92)
Sex
Men 31 (62%) 25 (50%)
Women 19 (38%) 25 (50%)
Fitzpatrick skin type
I 8 (16%) 4 (8%)
II 32 (64%) 43 (86%)
III 10 (20%) 3 (6%)
BCC in medical history
Yes 34 (68%) 37 (74%)
No 15 (30%) 13 (26%)
Study site
Academic Medical Centre 37 (74%) 38 (76%)
Netherlands Cancer Institute 13 (26%) 12 (24%)
Immunocompromised†
Yes 4 (8%) 4 (8%)
No 46 (92%) 46 (92%)
Tumour diameter (mm) 8 (3–15) 8 (3–20)
Tumour location
Head/neck 9 (18%) 12 (24%)
Trunk 32 (64%) 30 (60%)
Arm 4 (8%) 7 (14%)
Leg 5 (10%) 1 (2%)
Number of BCC 40 (80%) 33 (66%)
BCC subtype distribution‡
Superficial BCC 17 (43%) 14 (42%)
Nodular BCC 17 (43%) 17 (52%)
Aggressive BCC 6 (14%) 2 (6%)
†Patients who were taking immunosuppressive drugs such as oral steroids,
methotrexate, ciclosporin for suppression of immunological disorder, or to
prevent transplant rejection.
‡This number represents the histologically confirmed basal cell carcinoma
based on surgical excision specimen. Basal cell carcinoma subtype distribu-
tion according to the most aggressive subtype found at histology of surgical
excision.
Continuous variables are expressed as mean (range) and categorical vari-
ables as n (%).
BCC, basal cell carcinoma.
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Limitations of our study include the limited sample size of
aggressive BCC. Our randomized controlled trial was primar-
ily designed and powered to assess non-inferiority of a RCM
one-stop-shop in terms of tumour-free margins after surgical
treatment of BCC compared to standard care.12 Another
important limitation that needs to be considered when inter-
preting the results is the potential bias in favour of the
punch biopsy diagnosis. Although in line with current prac-
tice, the pathologists were not blinded to the results of the
punch biopsy during assessment of surgical excision specimen
in the standard care group. Lastly, BCCs on high-risk areas
of the face were excluded due to technical limitations of the
VivaScope 1500 device. This needs to be considered in
terms of external validity. Nonetheless the potential value of
RCM remains very high in the excluded patient population
since the introduction of the VivaScope 3000 flexible hand-
held version (VivaScope 3000; CaliberID; MAVIG GmbH),
that permits imaging of the more concave and convex high-
risk facial areas.23
Based on our findings, we believe that RCM could potentially
replace a punch biopsy for diagnosing and subtyping selected
BCC cases. Yet prior to doing so, it is mandatory to wait for the
results of future and ongoing larger prospective clinical trials.24
Besides RCM, more and more studies are reporting on the added
value of optical coherence tomography (OCT) for diagnosing
and subtyping BCC.25–28 In addition, a first report on a com-
bined RCM/OCT skin modality for ex vivo BCC detection has
been published.29 This approach could potentially be of signifi-
cant interest for diagnosing and subtyping BCC in clinical prac-
tice as it combines the detailed features of RCM with the in-
depth advantages of OCT.
Finally, we underline that both routine histology as non-inva-
sive skin imaging modalities such as RCM and OCT remain
morphology based and thus subject to interpretation bias.
Table 2 Diagnostic performance of RCM vs. a punch biopsy in diagnosing BCC compared to surgical excision
RCM (DK/YE) trial period Surgical excision Total
BCC No BCC
BCC 38 5 43
No BCC 0 3 3
Total 38 8 46
Punch biopsy trial period Surgical excision Total
BCC No BCC
BCC 31 3 34
No BCC 2 11 13
Total 33 14 47
RCM expert (MU) after trial period Surgical excision Total
BCC No BCC
BCC 27 2 29
No BCC 0 6 6
Total 27 8 35
RCM expert (CL) after trial period Surgical excision Total
BCC No BCC
BCC 24 2 26
No BCC 0 6 6
Total 24 8 32
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Bold numbers indicate concordant cases. Values in brackets are 95% confident intervals.
BCC, basal cell carcinoma; LR, likelihood ratio; NPV, negative predictive value; PPV, positive predictive value; RCM, reflectance confocal microscopy imaging.
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In conclusion, RCM and punch biopsy have comparable diag-
nostic accuracy to diagnose and subtype BCC depending on
RCM experience. Although experienced RCM users could accu-
rately diagnose BCC at a distance, we found an important differ-
ence in subtyping BCC. Future RCM studies need to focus on
diagnostic accuracy, reliability and specific criteria to improve
BCC subtype differentiation.
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